Home › Asset managers › Compare 2024-2025 › Vanguard vs DWS
Vanguard 2024-2025 · DWS 2024-2025 · Download the item list (CSV)
| Common items | Same | Differ | Split (not in %) | Same position | Fund-level | |
|---|---|---|---|---|---|---|
| All ballot items | 73,972 | 68,588 | 4,094 | 1,290 | 94.4% | 93.5% |
| Board proposals | 57,594 | 53,105 | 3,450 | 1,039 | 93.9% | 93.1% |
| E&S shareholder proposals | 254 | 129 | 69 | 56 | 65.2% | 56.0% |
| Other items | 16,124 | 15,354 | 575 | 195 | 96.4% | 95.9% |
Everything Voted differently Split votes
All ballot items Board proposals E&S shareholder proposals Other items
4,489 items. “Voted differently”: each manager’s funds all voted one way, and the two ways differ. “Split”: at least one manager’s funds did not all vote the same way.
| Company | Meeting | Proposal | On the ballot from | Board recommended | Vanguard | DWS |
|---|---|---|---|---|---|---|
| CRICUT INC. | May 28, 2025 | Election of Directors: Melissa Reiff Director Elections |
Board | For | FOR 12 funds |
WITHHOLD 1 fund |
| CRICUT INC. | May 28, 2025 | Election of Directors: Russell Freeman Director Elections |
Board | For | FOR 12 funds |
WITHHOLD 1 fund |
| CRICUT INC. | May 28, 2025 | Election of Directors: Steven Blasnik Director Elections |
Board | For | FOR 12 funds |
WITHHOLD 1 fund |
| CRINETICS PHARMACEUTICALS INC. | June 11, 2025 | To elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders: Matthew K. Fust Director Elections |
Board | For | FOR 15 funds |
WITHHOLD 1 fund |
| CROMWELL PROPERTY GROUP | November 29, 2024 | Approve Remuneration Report Compensation |
Board | For | FOR 7 funds |
AGAINST 1 fund |
| CRRC CORPORATION LTD. | June 18, 2025 | Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights for Additional A Shares and H Shares Capital Structure |
Board | For | FOR 6 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Attribution of Profit and Loss During the Transition Period Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Audit Report, Pro Forma Review Report and Valuation Report in Relation to the Transaction Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Authorization of the Board and Its Authorized Persons to Handle All Related Matters Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Completeness and Compliance of Implementation of Legal Proceedings of the Transaction and Validity of the Submitted Legal Documents Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Confidentiality Measures and Confidentiality System Adopted for This Transaction Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Description of the Basis and Fairness and Reasonableness of the Pricing of the Transaction Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Distribution Arrangement of Undistributed Earnings Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Fluctuation of the Company's Stock Price Before the Release of Information on This Transaction Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Impact of Dilution of Current Returns on Major Financial Indicators, the Relevant Measures to be Taken and Commitment from Relevant Parties Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Independence of Appraiser, the Validity of Hypothesis, the Relevance of Valuation Method and Purpose and Approach as Well as the Fairness of Pricing Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Issue Amount Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Issue Amount and Number of Issues Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Issue Manner and Target Subscribers Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Issue Type, Par Value and Listing Location Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Lock-Up Period Arrangement Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Overall Plan Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Performance Commitment and Compensation Arrangement Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Pricing Reference Date and Issue Price Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Purchases and Sales of Assets in the Twelve Months Prior to the Transaction Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Report (Draft) and Summary on Issuance of Shares and Acquisition by Cash as Well as Raising Supporting Funds and Related Party Transactions Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Report on the Usage of Previously Raised Funds Capital Structure |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Resolution Validity Period Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Signing of Conditional Agreement to the Issuance of Shares and Acquisition by Cash as well as Performance Compensation Agreement Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Target Assets Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Transaction Complies With Article 18 and 21 of the Measures for the Continuous Supervision of ChiNext Listed Companies (Trial) and Article 8 of the Shenzhen Stock Exchange Listed Company Major Asset Restructuring Review Rules Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Transaction Complies With Article 4 of Guidelines for the Supervision of Listed Companies No. 9 - Regulatory Requirements for Listed Companies to Plan and Implement Major Asset Restructuring Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Transaction Complies with Articles 11 and 43 of the Measures for the Administration of Major Asset Restructuring of Listed Companies Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Transaction Complies with the Relevant Provisions of the Administrative Measures for the Registration of Securities Issuance of Listed Companies Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Transaction Constitute as Major Asset Restructuring and Does Not Constitute as Restructuring and Listing Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Transaction Parties Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Transaction Price and Payment Method Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Use of Proceeds Capital Structure |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve the Company's Plan for Issuance of Shares and Acquisition by Cash as Well as Raising Supporting Funds Complies with Relevant Laws and Regulations Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve the Relevant Entity of Transaction Does Not Exist in Article 12 of Listed Company Supervision Guidelines No. 7 and Article 30 of the Guidelines for Self-regulatory Supervision No. 8 (Revised in 2023) Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 2 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | April 15, 2025 | Approve Use of Idle Raised Funds and Own Funds for Cash Management Extraordinary Transactions |
Board | For | FOR 5 funds |
AGAINST 1 fund |
| CSX CORP. | May 7, 2025 | Election of Directors: John J. Zillmer Director Elections |
Board | For | FOR 27 funds |
AGAINST 11 funds |
| CTBC FINANCIAL HOLDING CO. LTD. | June 13, 2025 | Approve Issuance of Restricted Stocks Compensation |
Board | For | FOR 6 funds |
AGAINST 3 funds |
| CTP N.V. | April 22, 2025 | AUTHORIZE BOARD TO EXCLUDE PREEMPTIVE RIGHTS FROM SHARE ISSUANCES Capital Structure |
Board | For | FOR 8 funds |
AGAINST 4 funds |
| CTP N.V. | April 22, 2025 | GRANT BOARD AUTHORITY TO ISSUE SHARES UP TO 10 PERCENT OF ISSUED CAPITAL FOR GENERAL PURPOSES AND ADDITIONAL 10 PERCENT OF ISSUED CAPITAL IN CASE OF MERGERS, ACQUISITIONS, OR STRATEGIC ALLIANCES Capital Structure |
Board | For | FOR 8 funds |
AGAINST 4 funds |
| CTS EVENTIM AG & CO. KGAA | May 21, 2025 | Approve Remuneration Policy Compensation |
Board | For | FOR 5 funds |
AGAINST 7 funds |
| CURBLINE PROPERTIES CORP. | May 7, 2025 | Election of two Class I Directors: Linda B. Abraham Director Elections |
Board | For | FOR 18 funds |
AGAINST 1 fund |
| CUTERA INC. | July 15, 2024 | Approval of the amendment and restatement of our 2019 Equity Incentive Plan to increase the total shares available for issuance under the 2019 Equity Incentive Plan by 2,395,275 shares. Compensation |
Board | For | FOR 9 funds |
AGAINST 1 fund |
| CUTERA INC. | July 15, 2024 | Election of Directors: Jeryl Hilleman Director Elections |
Board | For | FOR 9 funds |
AGAINST 1 fund |
| CUTERA INC. | July 15, 2024 | Election of Directors: Keith Sullivan Director Elections |
Board | For | FOR 9 funds |
AGAINST 1 fund |
| CVR ENERGY INC. | June 5, 2025 | To approve the Third Amended & Restated CVR Energy, Inc. 2007 Long-Term Incentive Plan. Compensation |
Board | For | FOR 15 funds |
AGAINST 1 fund |
| CVRX INC. | June 3, 2025 | Election of Class I Directors: Mitch Hill Director Elections |
Board | For | FOR 7 funds |
WITHHOLD 1 fund |
| CVS HEALTH CORP. | May 15, 2025 | Election of Directors: Leslie V. Norwalk Director Elections |
Board | For | FOR 31 funds |
AGAINST 9 funds |
| D'IETEREN GROUP | December 6, 2024 | Approve Dividends Capital Structure |
Board | For | FOR 6 funds |
AGAINST 6 funds |
| DAH SING BANKING GROUP LTD. | May 30, 2025 | Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights Capital Structure |
Board | For | FOR 7 funds |
AGAINST 1 fund |
| DAIDO STEEL CO. LTD. | June 25, 2025 | Elect Director Ishiguro, Takeshi Director Elections |
Board | For | FOR 6 funds |
AGAINST 1 fund |
| DAIDO STEEL CO. LTD. | June 25, 2025 | Elect Director and Audit Committee Member Niwa, Tetsuya Director Elections |
Board | For | AGAINST 6 funds |
FOR 1 fund |
| DAILY JOURNAL CORP. | February 19, 2025 | Election of four Directors: John B. Frank Director Elections |
Board | For | FOR 10 funds |
AGAINST 1 fund |
| DAILY JOURNAL CORP. | February 19, 2025 | Election of four Directors: Mary Conlin Director Elections |
Board | For | FOR 10 funds |
AGAINST 1 fund |
| DAILY JOURNAL CORP. | February 19, 2025 | Election of four Directors: Steven Myhill-Jones Director Elections |
Board | For | FOR 10 funds |
AGAINST 1 fund |
| DAIWA HOUSE INDUSTRY CO. LTD. | June 27, 2025 | Appoint Statutory Auditor Oyaide, Ryuichi Compensation |
Board | For | AGAINST 8 funds |
FOR 8 funds |
| DAIWA HOUSE INDUSTRY CO. LTD. | June 27, 2025 | Appoint Statutory Auditor Takashige, Yoshihiro Compensation |
Board | For | AGAINST 8 funds |
FOR 8 funds |
| DAKOTA GOLD CORP. | May 13, 2025 | Election of Directors: Alice Schroeder Director Elections |
Board | For | WITHHOLD 8 funds |
FOR 1 fund |
| DAKOTA GOLD CORP. | May 13, 2025 | Election of Directors: Amy K. Koenig Director Elections |
Board | For | WITHHOLD 8 funds |
FOR 1 fund |
| DAKOTA GOLD CORP. | May 13, 2025 | Election of Directors: Jennifer S. Grafton Director Elections |
Board | For | WITHHOLD 8 funds |
FOR 1 fund |
| DANIELI & C. OFFICINE MECCANICHE SPA | October 25, 2024 | Authorize Share Repurchase Program and Reissuance of Repurchased Shares Capital Structure |
Board | For | FOR 6 funds |
AGAINST 1 fund |
| DANIMER SCIENTIFIC INC. | July 9, 2024 | Approval of an amendment to the Company's 2020 Long-Term Incentive Plan. Compensation |
Board | For | FOR 8 funds |
AGAINST 1 fund |
| DANIMER SCIENTIFIC INC. | July 9, 2024 | Election of Directors: Allison M. Leopold Tilley Director Elections |
Board | For | FOR 8 funds |
WITHHOLD 1 fund |
| DANIMER SCIENTIFIC INC. | July 9, 2024 | Election of Directors: John P. Amboian Director Elections |
Board | For | FOR 8 funds |
WITHHOLD 1 fund |
| DANIMER SCIENTIFIC INC. | July 9, 2024 | Election of Directors: Philip Gregory Calhoun Director Elections |
Board | For | FOR 8 funds |
WITHHOLD 1 fund |
| DANSKE BANK A/S | March 20, 2025 | Approve Remuneration Policy Compensation |
Board | For | FOR 7 funds |
AGAINST 7 funds |
| DAQIN RAILWAY CO. LTD. | May 21, 2025 | Approve to Authorize the Board of Directors to Decide on the Company's Interim Profit Distribution Capital Structure |
Board | For | FOR 5 funds |
AGAINST 3 funds |
| DASSAULT AVIATION SA | May 16, 2025 | Authorize Repurchase of Up to 10 Percent of Issued Share Capital Capital Structure |
Board | For | FOR 5 funds |
AGAINST 6 funds |
| DASSAULT SYSTEMES SE | May 22, 2025 | Elect Marie-Helene Habert-Dassault as Director Director Elections |
Board | For | FOR 5 funds |
AGAINST 8 funds |
| DAVE & BUSTER'S ENTERTAINMENT INC. | June 18, 2025 | Approval of 2025 Omnibus Incentive Plan Compensation |
Board | For | FOR 15 funds |
AGAINST 1 fund |
| DAVE INC. | June 2, 2025 | Director Election: Michael Pope Director Elections |
Board | For | FOR 8 funds |
WITHHOLD 1 fund |
| DAVE INC. | June 2, 2025 | Director Election: Yadin Rozov Director Elections |
Board | For | FOR 8 funds |
WITHHOLD 1 fund |
| DAVIDE CAMPARI-MILANO NV | April 16, 2025 | Reelect Alessandra Garavoglia as Non-Executive Director Director Elections |
Board | For | FOR 5 funds |
AGAINST 5 funds |
| DAVIDE CAMPARI-MILANO NV | April 16, 2025 | Reelect Christophe Navarre as Non-Executive Director Director Elections |
Board | For | AGAINST 5 funds |
FOR 5 funds |
| DAVIDE CAMPARI-MILANO NV | April 16, 2025 | Reelect Emmanuel Babeau as Non-Executive Director Director Elections |
Board | For | AGAINST 5 funds |
FOR 5 funds |
| DAVIDE CAMPARI-MILANO NV | April 16, 2025 | Reelect Eugenio Barcellona as Non-Executive Director Director Elections |
Board | For | AGAINST 5 funds |
FOR 5 funds |
| DAVIDE CAMPARI-MILANO NV | April 16, 2025 | Reelect Luca Garavoglia as Non-Executive Director Director Elections |
Board | For | FOR 5 funds |
AGAINST 5 funds |
| DAY ONE BIOPHARMACEUTICALS INC. | June 2, 2025 | Election of Class I Directors: Garry Nicholson Director Elections |
Board | For | FOR 12 funds |
WITHHOLD 1 fund |
| DELIVERY HERO SE | June 18, 2025 | Approve Creation of EUR 10 Million Pool of Authorized Capital 2025/IV with or without Exclusion of Preemptive Rights Capital Structure |
Board | For | FOR 6 funds |
AGAINST 5 funds |
| DELIVERY HERO SE | June 18, 2025 | Approve Creation of EUR 14.7 Million Pool of Authorized Capital 2025/II with or without Exclusion of Preemptive Rights Capital Structure |
Board | For | FOR 6 funds |
AGAINST 5 funds |
| DELIVERY HERO SE | June 18, 2025 | Approve Creation of EUR 14.7 Million Pool of Authorized Capital 2025/III with or without Exclusion of Preemptive Rights Capital Structure |
Board | For | FOR 6 funds |
AGAINST 5 funds |
| DELIVERY HERO SE | June 18, 2025 | Approve Issuance of Warrants/Bonds with Warrants Attached/Convertible Bonds without Preemptive Rights up to Aggregate Nominal Amount of EUR 3 Billion; Approve Creation of EUR 14.7 Million Pool of Conditional Capital 2025/I to Guarantee Conversion Rights Capital Structure |
Board | For | FOR 6 funds |
AGAINST 5 funds |
| DELTA AIR LINES INC. | June 19, 2025 | Election of Nominees for Director: Sergio A. L. Rial Director Elections |
Board | For | FOR 31 funds |
AGAINST 10 funds |
| DENALI THERAPEUTICS INC. | June 3, 2025 | ELECTION OF DIRECTORS: Julian Baker Director Elections |
Board | For | FOR 13 funds |
WITHHOLD 1 fund |
| DENKA CO. LTD. | June 20, 2025 | Elect Director Imai, Toshio Director Elections |
Board | For | FOR 7 funds |
AGAINST 3 funds |
| DENKA CO. LTD. | June 20, 2025 | Elect Director Ishida, Ikuo Director Elections |
Board | For | FOR 7 funds |
AGAINST 3 funds |
| DENKA CO. LTD. | June 20, 2025 | Elect Director and Audit Committee Member Uchida, Mizuhiro Director Elections |
Board | For | AGAINST 7 funds |
FOR 3 funds |
| DENTSU GROUP INC. | March 28, 2025 | Elect Director Igarashi, Hiroshi Director Elections |
Board | For | FOR 7 funds |
AGAINST 4 funds |
| DENTSU SOKEN INC. | March 24, 2025 | Elect Director and Audit Committee Member Sekiguchi, Atsuhiro Director Elections |
Board | For | FOR 7 funds |
AGAINST 1 fund |
| DERICHEBOURG SA | January 29, 2025 | Authorize Repurchase of Up to 10 Percent of Issued Share Capital Capital Structure |
Board | For | FOR 4 funds |
AGAINST 1 fund |
| DESPEGAR.COM CORP. | December 12, 2024 | Elect Director Michael James Doyle Director Elections |
Board | For | FOR 9 funds |
AGAINST 1 fund |
| DETERRA ROYALTIES LTD. | October 24, 2024 | Approve Grant of STI Rights and LTI Rights to Julian Andrews Compensation |
Board | For | FOR 7 funds |
AGAINST 1 fund |
| DETERRA ROYALTIES LTD. | October 24, 2024 | Elect Jennifer Seabrook as Director Director Elections |
Board | For | FOR 7 funds |
AGAINST 1 fund |
| DEUTSCHE BANK AG | May 22, 2025 | APPROVE ALLOCATION OF INCOME AND DIVIDENDS OF EUR 0.68 PER SHARE Capital Structure |
Board | For | FOR 7 funds |
ABSTAIN 6 funds |
| DEUTSCHE BANK AG | May 22, 2025 | APPROVE CREATION OF EUR 2 BILLION POOL OF CAPITAL WITH PREEMPTIVE RIGHTS Capital Structure |
Board | For | FOR 7 funds |
ABSTAIN 6 funds |
← Previous Page 9 of 45 Next →
How items are matched and positions counted: see the comparison table and the methodology. Built October 25, 2026 from SEC Form N-PX filings.